Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Role of adiponectin in the pathology of early-stage coronary heart disease in Chinese Type 2 diabetes mellitus patients

Biling Ye¹, Ling Zeng², Zhan Xu¹, Wenji Lin¹

¹Department of Intensive Care Unit; ²Department of Nursing, Shenzhen Nanshan District Shekou People’s Hospital, Shenzhen 518067, China.

For correspondence:- Wenji Lin Email: IanAlvisuMvFn@yahoo.com

Accepted: 21 October 2020 Published: 30 November 2020

Citation: Ye B, Zeng L, Xu Z, Lin W. Role of adiponectin in the pathology of early-stage coronary heart disease in Chinese Type 2 diabetes mellitus patients. Trop J Pharm Res 2020; 19(11):2447-2452 doi: 10.4314/tjpr.v19i11.28

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the role of adiponectin in the pathogenesis of diabetes-induced coronary heart disease (CHD) in Chinese type 2 diabetes mellitus (T2DM) patients.

Methods: Serum ADpN levels were measured every 3 months in T2DM patients in early stage of heart disease who were followed up for 5 years. Adiponectin (ADpN) was measured using a turbidimetric immunoassay method. At the same time, ADpN was measured every 3 months for up to 5 years in T2DM patients with no sign of heart diseases (control). Hazard ratios (HR) for analysis of progression-free survival outcomes were assessed using appropriate statistical tools.

Results: At baseline, ADpN levels in male and female patients were similar (p < 0.05). However, male and female T2DM patients who developed heart disease had history of uncontrolled diabetes, dyslipidemia and hypertension. Patients (males and females) who had significantly lower levels of HDL developed heart disease (p < 0.05). The hazard ratio (HR) for low ADpN was favorable in male and female patients with early heart disease who experienced heart disease after baseline demography covariates such as age, BMI and gender.

Conclusion: These results suggest that low ADpN level is a significant independent potential risk factor for CHD in Chinese T2DM patients with early stage of cardiac disease who were taking biguanide- and thiazolidinedione-based drugs. Intervention strategies that raise ADpN levels > 7.0 μg/ml could be helpful in preventing CHD in these T2DM patients.

Keywords: Adiponectin, Coronary heart disease, Early-stage heart disease, Diabetes